MeiraGTx and Hologen AI Form $430 Million Joint Venture to Accelerate AI-Driven Gene Therapy for Parkinson's Disease

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - MeiraGTx Hldgs (NASDAQ:MGTX)

On Thursday, MeiraGTx Holdings plc MGTX announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. MeiraGTx will receive $200 million in upfront cash, and MeiraGTx and Hologen are forming a joint venture, Hologen Neuro AI Ltd. Also Read: Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints Additionally, the joint venture, Hologen Neuro AI Ltd, will be funded with capital of up to $230 million from Hologen to fully finance the development of AAV-GAD for Parkinson's disease through commercialization. Hologen will also fund earlier-stage clinical programs in the central nervous system (CNS), including AAV-BDNF for genetic obesity. Hologen will contribute its multi-modal generative foundation models (LMMs) to the joint venture. In forming this joint venture, MeiraGTx and Hologen have created the first neuro-AI clinical drug development company. MeiraGTx will retain 30% ownership in the Hologen Neuro AI Ltd joint venture and will lead all clinical development and manufacturing. MeiraGTx will also enter into exclusive clinical and commercial manufacturing supply agreements with the joint venture. In addition, Hologen will own a minority stake in MeiraGTx's manufacturing subsidiary and contribute to its annual funding. Hologen is deploying its generative AI capabilities to further optimize MeiraGTx's proprietary manufacturing capabilities by utilizing MeiraGTx's unique data lakes, which were built over nine years of development of MeiraGTx's manufacturing platform process. MeiraGTx's AAV-GAD program for Parkinson's disease is Phase 3 ready, with commercial manufacturing ongoing in-house at MeiraGTx. The transactions are expected to close in the second calendar quarter of 2025. Price Action: At the last check Thursday, MGTX stock was up 24.80% to $8.00. Also Read: Rise Of DeepSeek And Trump Tariff Threats Hurt Taiwan Stocks Including Taiwan Semiconductor Photo via Shutterstock MGTXMeiraGTx Holdings PLC$7.8522.5%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum89.66Growth93.94Quality-Value12.19Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

MeiraGTx stock surges on Hologen AI deal By Investing.com

Investing.com -- Shares of MeiraGTx Holdings plc (Nasdaq: NASDAQ:MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 development of AAV-GAD for Parkinson's Disease and enhancing the company's manufacturing processes. The London and New York-based clinical stage genetic medicines company disclosed the partnership on March 13, 2025, revealing substantial financial commitments from Hologen AI. MeiraGTx is set to receive $200 million in upfront cash and will form a joint venture with Hologen called Hologen Neuro AI Ltd. This venture will be supported by an additional $230 million from Hologen, designated for the complete financing of the AAV-GAD program through to its commercialization, as well as the advancement of other early-stage clinical programs. In this groundbreaking collaboration, MeiraGTx retains a 30% ownership stake in the joint venture and will take the lead on all clinical development and manufacturing activities. Additionally, Hologen will acquire a minority stake in MeiraGTx's manufacturing subsidiary, contributing to its annual funding and leveraging AI technologies to optimize MeiraGTx's proprietary manufacturing processes. MeiraGTx's AAV-GAD program has shown promise, with positive data from its randomized, sham-controlled clinical bridging study announced in October 2024. The study demonstrated significant improvement in the Unified Parkinson's Disease Rating Scale and quality of life measures, bolstering the potential of AAV-GAD as a treatment for Parkinson's disease. The CEO of MeiraGTx, Dr. Alexandria Forbes, expressed enthusiasm about the partnership's potential to enhance the robustness and success probability of the AAV-GAD Phase 3 clinical study. She highlighted the financial significance of the transaction, which provides MeiraGTx with a substantial cash infusion and funds a portion of its manufacturing operations, while retaining significant equity value in the fully funded late-stage Neuro-AI company. The transactions are subject to customary closing conditions and are expected to be finalized in the second quarter of 2025. This strategic move has clearly resonated with investors, as evidenced by the uptick in MeiraGTx's stock price, reflecting confidence in the company's enhanced prospects for developing treatments for neurological disorders.

MeiraGTx Holdings plc Enters into Strategic Collaboration with Hologen Limited to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

MeiraGTx Holdings plc announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. MeiraGTx will receive $200 million in upfront cash at closing and MeiraGTx and Hologen are forming a joint venture, called Hologen Neuro AI Ltd. In addition to the $200 million upfront payment to MeiraGTx, the joint venture, Hologen Neuro AI Ltd, will be funded with committed capital of up to $230 million from Hologen to fully finance the development of AAV-GAD for the treatment of Parkinson's disease through to commercialization, as well as funding earlier stage clinical programs in the CNS, including AAV-BDNF for genetic obesity. Hologen will contribute its proprietary multi-modal generative foundation models (LMMs) to the joint venture. Informing this joint venture, MeiraGTx and Hologicen have created the first neuro-AI clinical drug development company in which pioneering technologies from both companies will be deployed to transform the discovery and development of therapies targeting CNS circuitry in neurodegenerative and neuropsychiatric disorders. MeiraGTx will retain 30% ownership in the Hologen Neuro AI Ltd. joint venture and will lead all clinical development and manufacturing. MeiraGTx will also enter into exclusive clinical and commercial manufacturing supply agreements with the joint venture. In addition, Hologen will own a minority stake in MeiraGTx's manufacturing subsidiary and will contribute to the annual funding of the manufacturing subsidiary. MeiraGTx and HOLOGen will form a joint venture, Hologen neuro AI Ltd, with additional committed funding into the joint venture of up to $230 millionfrom Hologen to finance the development of the AAV-GAD program in Parkinson's disease through to commercialisation, as well as other locally-delivered therapies to the CNS. The joint venture, Hologen neurological AI Ltd, will use Hologen's proprietary multi-modal generatives foundation models (LMMs). MeiraGTx will hold a 30% ownership in the joint venture and will lead allclinical development and manufacturing.